Extrait

This is the first study of MLN3897 in any disease population. It seeks to establish: • The ability of MLN3897 to modify the signs and symptoms of rheumatoid arthritis (RA) • The safety and tolerability of MLN3897 in combination with methotrexate (MTX) • The pharmacokinetic (PK)/pharmacodynamic (PD) profile of MLN3897 in the RA population, and comparison to that in the healthy volunteer population with respect to CCR1 receptor blockade • MTX PK and MLN3897 PK and PD when these drugs are used in combination

Critère d'inclusion

• Rheumatoid Arthritis

Liens

• ictrp
• euctr
• ictrp
• ictrp
• euctr
• euctr